These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 10634372)

  • 21. A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with graves' ophthalmopathy.
    Zhu W; Ye L; Shen L; Jiao Q; Huang F; Han R; Zhang X; Wang S; Wang W; Ning G
    J Clin Endocrinol Metab; 2014 Jun; 99(6):1999-2007. PubMed ID: 24606088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiation therapy for Graves' ophthalmopathy: a systematic review and meta-analysis of randomized controlled trials.
    Viani GA; Boin AC; De Fendi LI; Fonseca EC; Stefano EJ; Paula JS
    Arq Bras Oftalmol; 2012 Oct; 75(5):324-32. PubMed ID: 23471326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A retrospective study on the efficacy of total absorbed orbital doses of 12, 16 and 20 Gy combined with systemic steroid treatment in patients with Graves' orbitopathy.
    Johnson KT; Wittig A; Loesch C; Esser J; Sauerwein W; Eckstein AK
    Graefes Arch Clin Exp Ophthalmol; 2010 Jan; 248(1):103-9. PubMed ID: 19865824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of somatostatin versus corticosteroid in the treatment of Graves' ophthalmopathy.
    Kung AW; Michon J; Tai KS; Chan FL
    Thyroid; 1996 Oct; 6(5):381-4. PubMed ID: 8936659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of 131 iodine therapy on the course of Graves' ophthalmopathy: a quantitative analysis of extraocular muscle volumes using orbital magnetic resonance imaging.
    Gupta MK; Perl J; Beham R; Sheeler LR; Foster JA; Gliga M; Mcbride N; Faiman MR; Mehta AE; Dattatreya R; Faiman C
    Thyroid; 2001 Oct; 11(10):959-65. PubMed ID: 11716044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy.
    Stan MN; Garrity JA; Bradley EA; Woog JJ; Bahn MM; Brennan MD; Bryant SC; Achenbach SJ; Bahn RS
    J Clin Endocrinol Metab; 2006 Dec; 91(12):4817-24. PubMed ID: 16984988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Orbital tissue-derived T lymphocytes from patients with Graves' ophthalmopathy recognize autologous orbital antigens.
    Otto EA; Ochs K; Hansen C; Wall JR; Kahaly GJ
    J Clin Endocrinol Metab; 1996 Aug; 81(8):3045-50. PubMed ID: 8768872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protracted hypofractionated radiotherapy for Graves' ophthalmopathy: a pilot study of clinical and radiologic response.
    Cardoso CC; Giordani AJ; Wolosker AM; Souhami L; Manso PG; Dias RS; Segreto HR; Segreto RA
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1285-91. PubMed ID: 21550180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study.
    Howarth D; Epstein M; Lan L; Tan P; Booker J
    Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy.
    Prummel MF; Mourits MP; Berghout A; Krenning EP; van der Gaag R; Koornneef L; Wiersinga WM
    N Engl J Med; 1989 Nov; 321(20):1353-9. PubMed ID: 2519530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative evaluation of extraocular muscle with high-field magnetic resonance in patients with Graves' ophthalmopathy with upper-lid retraction.
    Chen Y; Jin ZY; Zhang ZH; Xu DD; Meng W; Jiang B; Fang HY; Sun ZY; Chen Y; Sun HY; Feng F
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2012 Oct; 34(5):461-7. PubMed ID: 23134821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.
    Salvi M; Vannucchi G; Currò N; Campi I; Covelli D; Dazzi D; Simonetta S; Guastella C; Pignataro L; Avignone S; Beck-Peccoz P
    J Clin Endocrinol Metab; 2015 Feb; 100(2):422-31. PubMed ID: 25494967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Retrobulbar irradiation for Graves' ophthalmopathy -- long-term results].
    Pitz S; Kahaly G; Rösler HP; Krummenauer F; Wagner B; Stübler M; Pfeiffer N
    Klin Monbl Augenheilkd; 2002 Dec; 219(12):876-82. PubMed ID: 12548473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Short-tau inversion-recovery (STIR) sequence magnetic resonance imaging evaluation of orbital structures in Graves' orbitopathy].
    Rodríguez-González N; Pérez-Rico C; López-Para Giménez R; Arévalo-Serrano J; Del Amo García B; Calzada Domingo L; Flores Ruiz L; Blanco R
    Arch Soc Esp Oftalmol; 2011 Nov; 86(11):351-7. PubMed ID: 22040641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A quantitative method for assessing the degree of axial proptosis in relation to orbital tissue involvement in Graves' orbitopathy.
    Campi I; Vannucchi GM; Minetti AM; Dazzi D; Avignone S; Covelli D; Currò N; Ratiglia R; Guastella C; Pignataro L; Beck-Peccoz P; Salvi M
    Ophthalmology; 2013 May; 120(5):1092-8. PubMed ID: 23399378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An evaluation of supervoltage orbital irradiation for Graves' ophthalmopathy.
    Teng CS; Crombie AL; Hall R; Ross WM
    Clin Endocrinol (Oxf); 1980 Dec; 13(6):545-51. PubMed ID: 6784979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radioiodine-Associated Exacerbation of Graves' Orbitopathy in the Japanese Population: Randomized Prospective Study.
    Watanabe N; Noh JY; Kozaki A; Iwaku K; Sekiya K; Kosuga Y; Matsumoto M; Suzuki M; Yoshihara A; Ohye H; Kobayashi S; Kunii Y; Mukasa K; Sugino K; Inoue T; Ito K
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2700-8. PubMed ID: 25965082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Retrobulbar irradiation of endocrine ophthalmopathy: a comparison between 10 and 16 Gy total dose].
    Pfluger T; Wendt T; Toroutoglou N; Pickardt C; Wuttge R
    Strahlenther Onkol; 1990 Oct; 166(10):673-7. PubMed ID: 2237752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy of radiation therapy in the treatment of Graves' orbitopathy.
    Matthiesen C; Thompson JS; Thompson D; Farris B; Wilkes B; Ahmad S; Herman T; Bogardus C
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):117-23. PubMed ID: 21030157
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective and controlled study of ophthalmopathy after radioiodine therapy for Graves' hyperthyroidism.
    Manso PG; Furlanetto RP; Wolosker AM; Paiva ER; de Abreu MT; Maciel RM
    Thyroid; 1998 Jan; 8(1):49-52. PubMed ID: 9492153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.